In multiple myeloma, the anti-CXCR4 mAb ulocuplumab was recently shown to inhibit the malignant plasma cell dissemination by suppressing the EMT-like phenotype [40], and similar effects cannot be excluded in NETs. This evidence concerns the gene CXCR4 and AL amyloidosis.